An investigational triple-receptor agonist at the centre of metabolic research.
Retatrutide is an investigational peptide that has drawn heavy attention in metabolic research. It is not an approved medication, and Midas supplies it strictly as a research compound.
It is a single peptide designed to act at three receptors: GIP, GLP-1, and glucagon. That "triple agonist" design is what separates it from earlier compounds that target one or two of those receptors.
Researchers study how combining incretin and glucagon receptor activity affects energy-balance signalling pathways in models.
The compound is under investigation in clinical trials run by its developer. We do not summarise trial outcomes here; read the primary publications and registries directly.
Demand for this compound has produced many low-quality and mislabelled products. A batch-specific third-party COA with HPLC purity and mass-spec identity is the minimum standard. Here is how to read one, and what "third-party tested" actually means.
All of the above is research context. Compounds supplied by Midas are for laboratory research use only and are not for human consumption.
View GLP-3 research compound →